Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Long-Term Debt Repayments (2017 - 2022)

Sunshine Biopharma's Long-Term Debt Repayments history spans 7 years, with the latest figure at $1.9 million for Q1 2022.

  • For Q1 2022, Long-Term Debt Repayments rose 3858.33% year-over-year to $1.9 million; the TTM value through Dec 2022 reached $1.9 million, up 299.73%, while the annual FY2022 figure was $1.9 million, 299.73% up from the prior year.
  • Long-Term Debt Repayments reached $1.9 million in Q1 2022 per SBFM's latest filing, up from $23664.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $1.9 million in Q1 2022 to a low of -$767.0 in Q2 2019.
  • Average Long-Term Debt Repayments over 5 years is $248100.8, with a median of $53767.0 recorded in 2019.
  • Peak YoY movement for Long-Term Debt Repayments: plummeted 105.02% in 2019, then skyrocketed 3858.33% in 2022.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $48000.0 in 2018, then crashed by 101.6% to -$767.0 in 2019, then surged by 13998.31% to $106600.0 in 2020, then crashed by 77.8% to $23664.0 in 2021, then skyrocketed by 7929.07% to $1.9 million in 2022.
  • Per Business Quant, the three most recent readings for SBFM's Long-Term Debt Repayments are $1.9 million (Q1 2022), $23664.0 (Q4 2021), and $124309.0 (Q3 2021).